Name in SEC filings: ALNYLAM PHARMACEUTICALS, INC.
Source: ORION, orionbiotechai.com/company/ALNY, data as of Oct 13, 2026
https://www.orionbiotechai.com/company/ALNY
ALN-6400 · Topline/data readout · second half of 2026
SEC sources last checked .
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
Topline/data readoutsecond half of 2026
Stage: OtherSEC filing · “Phase 1; Phase 2”
Public float: $42,630,000,000 · as of · SEC filing
additional data from the Phase 1 clinical trial as well as initial results in the Phase 2 clinical trial in HHT the second half of 2026
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readoutsecond half of 2026
Stage: Phase 2SEC filing · “Phase 2”
Public float: $42,630,000,000 · as of · SEC filing
initial results in the Phase 2 clinical trial in HHT the second half of 2026
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readoutsecond half of 2026
Stage: OtherSEC filing · “Phase 1 and Phase 2; Phase 1”
Public float: $42,630,000,000 · as of · SEC filing
In the second half of 2026, Alnylam expects to announce clinical data from additional pipeline programs, including: • Results from Phase 1 and Phase 2 clinical trials of ALN-6400 in healthy volunteers and patients with hereditary hemorrhagic telangiectasia (HHT), respectively. • Results from a Phase 1 clinical trial of ALN-2232 in obesity and weight management.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readoutsecond half of 2026
Stage: Phase 1SEC filing · “Phase 1b”
Public float: $42,630,000,000 · as of · SEC filing
initiated a Phase 1b clinical trial of ALN-HTT02 in adult patients with HD and expect to present initial data from this trial in the second half of 2026.
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .
| Program / event | Stated period and SEC wording | Disclosure in stated period |
|---|---|---|
| ALN-2232Clinical results | second half of 2026“In the second half of 2026, Alnylam expects to announce clinical data from additional pipeline programs, including: • Results from Phase 1 and Phase 2 clinical trials of ALN-6400 in healthy volunteers and patients with hereditary hemorrhagic telangiectasia (HHT), respectively. • Results from a Phase 1 clinical trial of ALN-2232 in obesity and weight management.” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| ALN-6400Clinical results | second half of 2026“additional data from the Phase 1 clinical trial as well as initial results in the Phase 2 clinical trial in HHT the second half of 2026” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| ALN-6400Clinical results | second half of 2026“initial results in the Phase 2 clinical trial in HHT the second half of 2026” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| ALN-HTT02Clinical results | second half of 2026“initiated a Phase 1b clinical trial of ALN-HTT02 in adult patients with HD and expect to present initial data from this trial in the second half of 2026.” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| ALN-6400Clinical results | second half of 2026“additional data from the Phase 1 clinical trial as well as report clinical proof of concept in HHT in the second half of 2026” Filed · 10-K | Still within period As of Oct 19, 2026 |
| ALN-6400Clinical results | second half of 2026“Phase 2 clinical trial in patients with HHT, and we plan to share additional data from the Phase 1 clinical trial as well as report clinical proof of concept in HHT in the second half of 2026” Filed · 10-K | Still within period As of Oct 19, 2026 |
| ALN-HTT02Clinical results | second half of 2026“initiated a Phase 1b clinical trial of ALN-HTT02 in adult patients with HD (NCT06585449) and expect to present initial data from this trial in the second half of 2026.” Filed · 10-K | Still within period As of Oct 19, 2026 |
“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.
In late 2025, we initiated a Phase 2 clinical trial of ALN-6400 in patients with Hereditary Hemorrhagic Telangiectasia, or HHT, and we plan to share additional data from the Phase 1 clinical trial as well as initial results in the Phase 2 clinical trial in HHT the second half of 2026.
Historical summaries and source dates are retained separately from the SEC timing quotes above. Earlier publications were collected retrospectively.
Historical catalog checked .
Source published · Original announcement
Source-link check: this original issuer URL opened the press-release list in Chrome on . The original recorded URL is retained.Retained timing label: Early 2024
Retained summary: Alnylam expected the HELIOS-B Phase 3 topline results in early 2024. The company did not give an exact calendar deadline in this statement.
Source published · Original announcement
Source-link check: this original issuer URL opened the press-release list in Chrome on . The original recorded URL is retained.Retained timing label: Late June or early July 2024
Retained summary: Alnylam described changes to the statistical analysis plan, endpoint structure and study exposure, and expected topline results in late June or early July 2024. This records a changed timing statement, without assigning an invented day to either phrase.
Source published · Original announcement
Source-link check: this original issuer URL opened the press-release list in Chrome on . The original recorded URL is retained.Retained summary: Alnylam published HELIOS-B topline results and reported that the study met its primary and secondary endpoints. This is evidence that a readout was announced; it is not an independent review of every efficacy or safety claim.
Original ClinicalTrials.gov record · Open the selected study
These are selected linked records and dated source metadata, not a live registry recheck or the company’s full pipeline. Company announcements and the selected registry study are separate evidence sets. No stage or event timing is borrowed between them.
Coverage and identity checksSuggest an SEC timing statement to add for ALNY. You can include the original filing link in your note. The founder reads each request by hand.
Or email ORION.
See ALNY in the calendar · Review labels and methodology